Is Actinium Pharmaceuticals, Inc. overvalued or undervalued?

As of 15 May 2023, the valuation grade for Actinium Pharmaceuticals, Inc. moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently considered overvalued, particularly given its P/E ratio is not applicable due to losses, while its Price to Book Value stands at 2.22. Additionally, the EV to EBIT and EV to EBITDA ratios are both at a low 0.16, suggesting that the market is not valuing the company's earnings potential favorably.
In comparison to its peers, Actinium Pharmaceuticals has a valuation score of -0.9802, while Fusion Pharmaceuticals, Inc. has a P/E of -17.5788 and Zevra Therapeutics, Inc. has a P/E of -5.0550, both indicating a challenging environment for similar firms. The company's return over the past year has been particularly poor at -79.21%, contrasting sharply with the S&P 500's return of 10.26%, further reinforcing the notion that Actinium may not be a viable investment at its current valuation.